ATE292977T1 - Präsynaptische neurotoxine gegen migränekopfschmerzen - Google Patents

Präsynaptische neurotoxine gegen migränekopfschmerzen

Info

Publication number
ATE292977T1
ATE292977T1 AT00204206T AT00204206T ATE292977T1 AT E292977 T1 ATE292977 T1 AT E292977T1 AT 00204206 T AT00204206 T AT 00204206T AT 00204206 T AT00204206 T AT 00204206T AT E292977 T1 ATE292977 T1 AT E292977T1
Authority
AT
Austria
Prior art keywords
migraine headaches
presynaptic neurotoxins
presynaptic
mammal
neurotoxins
Prior art date
Application number
AT00204206T
Other languages
English (en)
Inventor
William J Binder
Original Assignee
William J Binder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE292977(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by William J Binder filed Critical William J Binder
Application granted granted Critical
Publication of ATE292977T1 publication Critical patent/ATE292977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00204206T 1994-05-09 1995-05-02 Präsynaptische neurotoxine gegen migränekopfschmerzen ATE292977T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24097394A 1994-05-09 1994-05-09
US34333194A 1994-11-21 1994-11-21

Publications (1)

Publication Number Publication Date
ATE292977T1 true ATE292977T1 (de) 2005-04-15

Family

ID=26933871

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00204206T ATE292977T1 (de) 1994-05-09 1995-05-02 Präsynaptische neurotoxine gegen migränekopfschmerzen
AT95918353T ATE215832T1 (de) 1994-05-09 1995-05-02 Botulinumtoxin zur reduktion von migraine - kopfschmerzen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95918353T ATE215832T1 (de) 1994-05-09 1995-05-02 Botulinumtoxin zur reduktion von migraine - kopfschmerzen

Country Status (12)

Country Link
US (1) US5714468A (de)
EP (2) EP1086702B1 (de)
JP (1) JP3066079B2 (de)
AT (2) ATE292977T1 (de)
AU (1) AU2431995A (de)
CA (2) CA2312047A1 (de)
DE (2) DE69526340T2 (de)
DK (2) DK1086702T3 (de)
ES (2) ES2238969T3 (de)
LU (1) LU92052I2 (de)
PT (2) PT758900E (de)
WO (1) WO1995030431A1 (de)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
DE69434008T2 (de) * 1993-12-28 2005-09-22 Allergan, Inc., Irvine Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
CA2319113A1 (en) 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
US7537773B1 (en) 1998-08-25 2009-05-26 Botulinum Toxin Research Associates, Inc. Chemodenervating pharmaceutical as anti-inflammatory agent
US6139545A (en) * 1998-09-09 2000-10-31 Vidaderm Systems and methods for ablating discrete motor nerve regions
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
AUPP627498A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
WO2000062746A1 (en) * 1999-04-16 2000-10-26 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6429189B1 (en) 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6753315B2 (en) 2000-02-24 2004-06-22 Brown University Research Foundation α-bungarotoxin molecules and uses thereof
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
CA2413301A1 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7223577B2 (en) * 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
BR0214126A (pt) * 2001-11-15 2004-10-13 Micro Algae Corp Composiçáo farmacêutica para interferir na transmissão neuronal, preparação para o rejuvenescimento facial, e, métodos para interferir na transmissão neuronal, e na contração muscular
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
AU2003212473A1 (en) * 2002-03-01 2003-09-16 Solstice Neurosciences, Inc. Methods of treating nerve entrapment syndromes
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
CA2501856A1 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US7758872B1 (en) * 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
EP1599213A4 (de) * 2003-02-24 2009-07-15 Ira Sanders Zellmembran-translokation von regulierten snare- inhibitoren, zusammensetzungen dafür und verfahren zur behandlung von erkrankungen
US8071550B2 (en) * 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
WO2004078200A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
ES2381091T3 (es) * 2003-03-06 2012-05-23 Botulinum Toxin Research Associates, Inc. Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica
WO2004084839A2 (en) * 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
BRPI0409478A (pt) 2003-04-16 2006-05-02 Allergan Inc dispositivo de injeção/aspiração de volume controlado
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
WO2006096164A1 (en) 2005-03-03 2006-09-14 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2005251676B2 (en) * 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
EP1824488B1 (de) * 2004-05-07 2017-08-09 Algenis SpA Phycotoxine und verwendungen damit
CA2607206C (en) * 2004-05-07 2016-06-14 Phytotox Limited Transdermal administration of phycotoxins
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
EP3153159A1 (de) 2004-07-09 2017-04-12 Robert Sabin Zusammensetzungen mit einer kupferverbindung zur behandlung von erkrankungen bei säugetieren
US20070258900A1 (en) * 2004-07-20 2007-11-08 Joseph Francis Blood Flow Assessment of Clostridial Toxin Applications
WO2006130161A2 (en) * 2004-07-21 2006-12-07 The Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
AU2012241076B2 (en) * 2005-02-01 2015-05-14 Allergan, Inc. Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
RU2007136616A (ru) * 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрескожного введения ботулинового токсина
US7731411B2 (en) * 2005-04-04 2010-06-08 Schlumberger Technology Corporation Circulating fluid system for powder fluidization and method of performing same
US20090214466A1 (en) * 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
DE102005058639A1 (de) * 2005-12-07 2007-07-26 Armin Maurer Behandlung von Trichodynie und anschwellender Arteria temporalis superficialis
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
JP2010519211A (ja) * 2007-02-15 2010-06-03 アラーガン、インコーポレイテッド 膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用
MX2010004488A (es) * 2007-10-23 2010-06-17 Allergan Inc Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
US8512715B2 (en) 2008-08-14 2013-08-20 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US9204925B2 (en) 2008-08-14 2015-12-08 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
EP2480250B1 (de) 2009-09-24 2014-04-16 Allergan, Inc. Zusammensetzungen Botulinumtoxin A oder B enthaltend zur Verwendung bei der Behandlung der Osteoporose
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US20130261062A1 (en) 2010-10-14 2013-10-03 Allergan, Inc. Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
WO2012103415A1 (en) 2011-01-28 2012-08-02 Allergan, Inc. Dosage regimen for the treatment of multiple disorders with botulinum toxins
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
KR20140054028A (ko) 2011-07-08 2014-05-08 알러간, 인코포레이티드 자율신경계 장애의 치료방법
CA2841917A1 (en) 2011-07-14 2013-01-17 Allergan, Inc. Methods for treatment of incontinence associated with sexual activity
BR112014001066A2 (pt) 2011-07-20 2017-02-21 Allergan Inc toxinas botulínicas para uso em um método para tratamento de depósitos adiposos
US8617569B2 (en) 2012-03-12 2013-12-31 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related foraminal sites
AU2013232758C1 (en) 2012-03-12 2015-03-05 William J. Binder Treatment of migraine headaches with presynaptic neurotoxin
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
EP2836193B1 (de) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Verbindungen zur hemmung neuronaler exozytose (ii)
CN104736166B (zh) 2012-05-30 2018-02-16 哈佛大学校长及研究员协会 工程化的肉毒神经毒素
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
WO2014078724A1 (en) 2012-11-16 2014-05-22 Finzi Eric Treatment of post-traumatic stress disorder using botulinum toxin a
KR20150135425A (ko) 2013-03-22 2015-12-02 리포텍 에스.에이. 피부, 점막 및/또는 손톱의 치료 및/또는 관리를 위한 세포외 다당류
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016149092A1 (en) 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
AU2017277905B2 (en) 2016-06-08 2022-04-14 Children's Medical Center Corporation Engineered Botulinum neurotoxins
FI3481852T3 (fi) 2016-07-08 2023-03-19 Childrens Medical Center Uusi botulinum-neurotoksiini ja sen johdannaisia
EP3504226A1 (de) 2016-08-24 2019-07-03 President and Fellows of Harvard College Manipuliertes botulinumneurotoxin
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
CA3035473A1 (en) 2016-09-13 2018-03-22 Allergan, Inc. Non-protein clostridial toxin compositions
WO2019067815A2 (en) 2017-09-29 2019-04-04 Children's Medical Center Corporation NEUROTOXIN-LIKE TOXIN AND USES THEREOF
EP3470054B1 (de) 2017-10-11 2023-09-20 Hugel Inc. Mikrostrukturformulierungstechniken für botulinumtoxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
LT3660509T (lt) 2018-11-29 2022-05-10 Hugel Inc. Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti
WO2020146333A1 (en) 2019-01-07 2020-07-16 Azizzadeh Babak Treatment of stress disorders, including post-traumatic stress disorder, using acetylcholine release inhibiting neurotoxic proteins to reduce stress levels
WO2021041978A1 (en) * 2019-08-30 2021-03-04 AEON Biopharma, Inc. Neurotoxin compositions for use in treating headache
TW202136518A (zh) 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
CA2153781A1 (en) * 1993-01-15 1994-07-21 Gary E. Borodic Method for treating myofascial pain syndrome
DE69434008T2 (de) * 1993-12-28 2005-09-22 Allergan, Inc., Irvine Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin

Also Published As

Publication number Publication date
PT1086702E (pt) 2005-08-31
AU2431995A (en) 1995-11-29
LU92052I2 (fr) 2013-04-03
EP1086702A2 (de) 2001-03-28
DE69534150D1 (de) 2005-05-19
EP0758900A4 (de) 1997-05-21
JPH10500406A (ja) 1998-01-13
WO1995030431A1 (en) 1995-11-16
CA2190011A1 (en) 1995-11-16
EP1086702A3 (de) 2001-04-04
ES2174945T3 (es) 2002-11-16
DE69526340T2 (de) 2002-11-14
EP1086702B1 (de) 2005-04-13
CA2312047A1 (en) 1995-11-16
EP0758900B1 (de) 2002-04-10
EP0758900A1 (de) 1997-02-26
ATE215832T1 (de) 2002-04-15
CA2190011C (en) 2000-09-26
US5714468A (en) 1998-02-03
JP3066079B2 (ja) 2000-07-17
DE69526340D1 (de) 2002-05-16
DE69534150T2 (de) 2006-02-16
PT758900E (pt) 2002-09-30
DK1086702T3 (da) 2005-05-23
DK0758900T3 (da) 2002-07-29
ES2238969T3 (es) 2005-09-16

Similar Documents

Publication Publication Date Title
ATE292977T1 (de) Präsynaptische neurotoxine gegen migränekopfschmerzen
ITMI911299A1 (it) Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
DE69329073T2 (de) In liposomen verkapseltes taxol und verwendungsverfahren
NO905322D0 (no) Aminosyrederivater.
FI920450A0 (fi) Metoder och kompositioner foer foerhindrande av symtomer av sepsis.
UA41355C2 (uk) Засіб для лікування нейро-сніду
BR0206549A (pt) Uso de flumazenil na produção de uma droga para o tratamento de dependência de álcool
DE69213935T2 (de) Neue heterocyclische carbonsäuren
SE0004101D0 (sv) New use
ES2139674T3 (es) Metodo para tratar la sintomatologia del sindrome premenstrual con vitamina d o vitamina d y calcio.
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
PT1181012E (pt) Valproato intravenoso para tratamento de enxaqueca aguda
EE200100026A (et) Oksasolidinoonid silmahaiguste raviks
GR3026428T3 (en) Optical isomers of 7- 3-(1,1-dialkylmethyl-1-amino-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents
AU4132397A (en) Therapeutic formulations containing venom or venom anti-serum either lone or in combination for the therapeutic prophylaxis and therapy of neoplasms
FI97884B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-dihydroksi-2,5-dihydrofuranonien valmistamiseksi
PT985414E (pt) Metodo de tratamento de glaucoma e retinopatia isquemica
DK0872239T3 (da) Anvendelse af olanzapin til fremstilling af et lægemiddel til behandling af cerebral fokal iskæmi
PT872238E (pt) Utilizacao de olanzapina para o fabrico de um medicamento para neuroproteccao

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1086702

Country of ref document: EP